StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Lynparza (olaparib) — Established RoW YoY CER by Quarter

Lynparza (olaparib) — Established RoW YoY CER (%) (%)

QuarterlyAnnual

AstraZeneca Lynparza (olaparib) — Established RoW YoY CER: 3.0% in Q2 2026, up 1.0 pts from a year earlier.

Latest, Q2 2026
3.0%
Period ended Jun 30, 2026
Change on a year earlier
+1.0 pts
2.0% in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Lynparza | 829 | | ( 1 ) | | ( 3 ) | | 351 | | ( 7 ) | | 170 | | 4 | | ( 2 ) | | 240 | | 5 | | 1 | | 68 | | ( 2 ) | | 3”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLynparza (olaparib) — Established RoW YoY CER (%) (%)Year on yearSource
Q2 2026Jun 30, 20263.0%+1.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20263.0%+1.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20256.0%+4.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20255.0%+13.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20252.0%+8.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20252.0%+8.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20242.0%0.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-8.0%-24.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-6.0%-21.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-6.0%-22.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20232.0%-13.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202316.0%+4.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202315.0%-8.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202316.0%-16.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202215.0%-13.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202212.0%-21.0 ptsForm 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Lynparza (olaparib) — Established RoW YoY CER (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-lynparza-erow-cer-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.